Figure 1. Flt3L combined with low-dose of Rapa prolongs cardiac allograft survival and attenuates infiltrates in the graft.

(A) Heart allograft survival. The cardiac allograft survival time in recipients treated with Flt3L (10 µg/day, i.v.) and low-dose of Rapa (2 mg/kg/day; p.o, POD0-15) was significant longer than those of the untreated and monotherapy groups (n = 10) (* P<0.05, combination therapy group vs. other groups). (B) Histology of cardiac allografts. Grafts were harvested at the time of rejection or at study endpoint (POD 100) and evaluated by H&E staining of paraffin sections (original magnification, ×200). The results are representative of three independently performed experiments.